Berg, Boehringer Ingelheim partner on inflammatory disease research

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/peterschreiber.media)
(Image: Getty/peterschreiber.media)

Related tags: Inflammation, Clinical research, data analysis

The research collaboration will seek to identify candidate biomarkers for a group of inflammatory conditions, using AI and other advanced technology.

Berg—a clinical-stage company that incorporates artificial intelligence (AI) to research various diseases and develop novel treatments for those conditions—is joining forces with pharmaceutical firm Boehringer Ingelheim, using its Interrogative Biology platform. The two firms will work together on research projects centered on better understanding the spectrum of inflammatory diseases, and their associated biological drivers.

According to Berg, the pilot program working with Boehringer Ingelheim is geared toward revealing new insights into the complexities of various inflammatory diseases. The possible outcomes of the research partnership, the participants hope, will lead to an increased understanding of the etiology of potential candidate biomarkers.

Niven Narain (Berg cofounder, president and CEO) said the two companies hope to advance tests and treatments for people diagnosed with such inflammatory diseases.

“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with Berg’s next generation AI-driven, patient-biology capability,” he said. “Our intent is for BergInterrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.

Berg in the past has collaborated with numerous pharmaceutical companies and applied its Interrogative Biology platform to diverse datasets, in order to address major unment clinical needs.

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars